•
Jun 30, 2021
Acumen Q2 2021 Earnings Report
Acumen Pharmaceuticals reported financial results for the second quarter of 2021 and provided business highlights.
Key Takeaways
Acumen Pharmaceuticals reported a net loss of $61.4 million for the second quarter of 2021. The company's cash, cash equivalents, and marketable securities were $68.8 million as of June 30, 2021. Acumen closed its initial public offering in July 2021, with net proceeds of $169 million.
Initiated ACU-001, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s Disease.
Closed initial public offering in July 2021, with aggregate net proceeds of $169 million.
Cash, cash equivalents and marketable securities were $68.8 million as of June 30, 2021.
Expect to report top-line data from ACU-001 trial by year end 2022.